Mylan offers EC concessions to get approval for $7.2 billion Meda buy

BRUSSELS – U.S. generic drugmaker Mylan NV has offered concessions in a bid to allay concerns by EU competition regulators over its proposed $7.2-billion acquisition of Swedish rival Meda , the…

Leave a Reply

Read the original at Reuters: Deals.